CD28 and T-cell non-Hodgkin lymphoma: Clinical trials on the efficacy in T-Cell lymphoma are rare, but one case report reports a rapid clinical response with the CTLA4 inhibitor ipilimumab in a patient with Sezary syndrome harboring a highly expressed gene fusion between CTLA4 and CD28 [69].